Literature DB >> 26133158

Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy.

Simon Greulich1, Ingrid Kindermann2, Julia Schumm3,4, Andrea Perne5, Stefan Birkmeier3, Stefan Grün3, Peter Ong3, Tim Schäufele3, Karin Klingel6, Steffen Schneider7, Reinhard Kandolf6, Michael Böhm2, Udo Sechtem3, Heiko Mahrholdt8.   

Abstract

OBJECTIVE: Primary objective was to establish the prognostic value of the myocardial load of PVB19 genomes in patients presenting for work-up of myocarditis and/or unclear cardiomyopathy in comparison to clinical, and CMR parameters.
METHODS: 108 consecutive patients who underwent EMB because of suspected myocarditis and/or unclear cardiomyopathy, and had evidence of myocardial PVB19 genome, were enrolled. Primary endpoint was all-cause mortality; secondary endpoint was a composite of cardiac mortality and hospitalization for heart failure.
RESULTS: Mean LV-EF was 40%. We found n = 27 patients to have a viral load ≥ 500 GE (IQR 559-846), n = 72 had 100-499 GE, and n = 9 had <100 GE. Immunohistology revealed chronic myocarditis in n = 66, acute myocarditis in n = 1, DCM in n = 17, PVB19 genome only in n = 13, and other pathologies in n = 11. During follow-up 11 patients died, two suffered SCD but were successfully shocked by ICD, and 21 were hospitalized for heart failure. Interestingly, not the viral load, but functional parameters such as LV-EF, LV-EDV (endpoint 2), as well as the histologic diagnosis of DCM and the presence of LGE (for all endpoints) reached statistical significance. In fact, the presence of LGE yields an odds-ratio for a lethal event of 8.56 (endpoint 1), and of 5.52 for endpoint 2. No patient with normal LV-EF, or the absence of LGE, suffered cardiac death during long-term follow-up.
CONCLUSION: The viral load of PVB19 genomes in the myocardium is not related to the long-term outcome. Furthermore, this study suggests a growing role of imaging for risk stratification in non-ischemic myocardial disease.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Mortality; Myocarditis; PVB19; Prognosis

Mesh:

Year:  2015        PMID: 26133158     DOI: 10.1007/s00392-015-0884-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  23 in total

1.  Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.

Authors:  Garrick C Stewart; Javier Lopez-Molina; Raju V S R K Gottumukkala; Gregg F Rosner; Mary S Anello; Jonathan L Hecht; Gayle L Winters; Robert F Padera; Kenneth L Baughman; Myra A Lipes
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

2.  Myocarditis; a classification of 1402 cases.

Authors:  I GORE; O SAPHIR
Journal:  Am Heart J       Date:  1947-12       Impact factor: 4.749

3.  An improved MR imaging technique for the visualization of myocardial infarction.

Authors:  O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

4.  Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging.

Authors:  Heiko Mahrholdt; Anja Wagner; Thomas A Holly; Michael D Elliott; Robert O Bonow; Raymond J Kim; Robert M Judd
Journal:  Circulation       Date:  2002-10-29       Impact factor: 29.690

5.  Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.

Authors:  Heiko Mahrholdt; Anja Wagner; Claudia C Deluigi; Eva Kispert; Stefan Hager; Gabriel Meinhardt; Holger Vogelsberg; Peter Fritz; Juergen Dippon; C-Thomas Bock; Karin Klingel; Reinhard Kandolf; Udo Sechtem
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

8.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

10.  Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology.

Authors:  Heiko Mahrholdt; Christine Goedecke; Anja Wagner; Gabriel Meinhardt; Anasthasios Athanasiadis; Holger Vogelsberg; Peter Fritz; Karin Klingel; Reinhard Kandolf; Udo Sechtem
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

View more
  7 in total

1.  Clinically suspected myocarditis with pseudo-infarct presentation: the role of endomyocardial biopsy.

Authors:  Alida L P Caforio; Giacomo Malipiero; Renzo Marcolongo; Sabino Iliceto
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 2.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

4.  Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.

Authors:  Heinz-Peter Schultheiss; Cornelia Piper; Olaf Sowade; Finn Waagstein; Joachim-Friedrich Kapp; Karl Wegscheider; Georg Groetzbach; Matthias Pauschinger; Felicitas Escher; Eloisa Arbustini; Harald Siedentop; Uwe Kuehl
Journal:  Clin Res Cardiol       Date:  2016-04-25       Impact factor: 5.460

5.  T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis.

Authors:  Ulf K Radunski; Gunnar K Lund; Dennis Säring; Sebastian Bohnen; Christian Stehning; Bernhard Schnackenburg; Maxim Avanesov; Enver Tahir; Gerhard Adam; Stefan Blankenberg; Kai Muellerleile
Journal:  Clin Res Cardiol       Date:  2016-07-07       Impact factor: 5.460

Review 6.  Myocarditis: A Clinical Overview.

Authors:  A L P Caforio; G Malipiero; R Marcolongo; S Iliceto
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 3.955

7.  Predictors of Mortality in Patients With Biopsy-Proven Viral Myocarditis: 10-Year Outcome Data.

Authors:  Simon Greulich; Andreas Seitz; Karin A L Müller; Stefan Grün; Peter Ong; Nawid Ebadi; Klaus Peter Kreisselmeier; Peter Seizer; Raffi Bekeredjian; Carolin Zwadlo; Christoph Gräni; Karin Klingel; Meinrad Gawaz; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Heart Assoc       Date:  2020-08-13       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.